Kirk Randal J, et al. – ‘SC 13D/A’ on 6/9/00 re: Clinical Data Inc

On:  Friday, 6/9/00, at 3:51pm ET   ·   Accession #:  916641-0-832   ·   File #:  5-39041

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Amendment to General Statement of Beneficial Ownership   —   Schedule 13D
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: SC 13D/A    Schedule 13D Amendment 2                               7     27K 
 2: EX-7        Joint Filing Agreement                                 1      6K 

SC 13D/A   —   Schedule 13D Amendment 2
Document Table of Contents

SC 13D/A
1st Page of 7
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D
Under the Securities Exchange Act of 1934 
(Amendment No. 2) 

NOVITRON INTERNATIONAL, INC.  
----------------------------  
(Name of Issuer)  

COMMON STOCK, $.01 par value per share  
--------------------------------------  
(Title of Class of Securities)

670088103 
--------- 
(CUSIP Number)  

Third Security, LLC 
The Governor Tyler  
1902 Downey Street  
Radford, Virginia 24141 
Attention: Marcus E. Smith, Esq.  
Telephone No.: 540-731-3344 
--------------------------- 
(Name, Address and Telephone Number of Person Authorized to   
Receive Notices and Communications) 

Copy to:  
John Owen Gwathmey, Esq.  
Hunton & Williams   
Riverfront Plaza, East Tower  
951 East Byrd Street  
Richmond, Virginia 23219  

June 8, 2000  
------------  
(Date of Event Which Requires Filing of This Statement) 

If the filing person has previously filed a statement   
on Schedule 13G to report the acquisition which is the  
subject of this Schedule 13D, and is filing this  
schedule because of Rules 13d-1(e), (f) or (g), 
check the following box [_].  

Page 1 of 8 Pages 

SC 13D/A
2nd Page of 7
TOC
1st
Previous
Next
↓Bottom
Just 2nd
--------------------------                            ------------------------  
CUSIP NO. 670088103                   13D              Page 2 of 8 Pages        
--------------------------                            ------------------------  

------------------------------------------------------------------------------  
1    NAME OF REPORTING PERSONS                                                
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)         

Randal J. Kirk                                                    
------------------------------------------------------------------------------  
2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP                (a) [_]  
                                                                   (b) [_]

------------------------------------------------------------------------------  
3    SEC USE ONLY                                                             

------------------------------------------------------------------------------  
4    SOURCE OF FUNDS                                                          

PF                                                                
------------------------------------------------------------------------------  
5    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT        
   TO ITEM 2(d) or 2(e)                                                [_]

------------------------------------------------------------------------------  
6    CITIZENSHIP OR PLACE OF ORGANIZATION                                     

United States                                                     
------------------------------------------------------------------------------  
NUMBER OF       7    SOLE VOTING POWER                                

                 -----------------------------------------------------------
SHARES         8    SHARED VOTING POWER                             

BENEFICIALLY              401,133                                         
                 -----------------------------------------------------------
OWNED BY        9    SOLE DISPOSITIVE POWER                           

EACH REPORTING                                                                
                 -----------------------------------------------------------
PERSON WITH        10   SHARED DISPOSITIVE POWER                            

401,133               
------------------------------------------------------------------------------  
11    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON              

401,133                                                           
------------------------------------------------------------------------------  
12    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES                    
   CERTAIN SHARES                                                      [_]

------------------------------------------------------------------------------  
13    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)                        

27.8%                                                             
------------------------------------------------------------------------------  
14    TYPE OF REPORTING PERSON                                                  

IN                                                                
------------------------------------------------------------------------------  

SC 13D/A
3rd Page of 7
TOC
1st
Previous
Next
↓Bottom
Just 3rd
--------------------------                            --------------------------
CUSIP NO. 670088103                  13D               Page 3 of 8 Pages        
--------------------------                            --------------------------

--------------------------------------------------------------------------------
1    NAME OF REPORTING PERSONS                                                
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)         

       Clinical Chemistry Holdings, Inc.   I.R.S. Identification No.: 52-2202556
--------------------------------------------------------------------------------
2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP                  (a) [_]
                                                                       (b) [_]

--------------------------------------------------------------------------------
3    SEC USE ONLY                                                             

--------------------------------------------------------------------------------
4    SOURCE OF FUNDS                                                          

WC                                                                
--------------------------------------------------------------------------------
5    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT        
     TO ITEM 2(d) or 2(e)                                                  [_]

--------------------------------------------------------------------------------
6    CITIZENSHIP OR PLACE OF ORGANIZATION                                     

Delaware                                                          
--------------------------------------------------------------------------------
NUMBER OF       7    SOLE VOTING POWER                                

                   -------------------------------------------------------------
SHARES         8    SHARED VOTING POWER                             

BENEFICIALLY              398,133                                         
                   -------------------------------------------------------------
OWNED BY        9    SOLE DISPOSITIVE POWER                           

EACH REPORTING                                                                
                   -------------------------------------------------------------
PERSON WITH        10   SHARED DISPOSITIVE POWER                            

398,133               
--------------------------------------------------------------------------------
11    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON              

398,133                                                           
--------------------------------------------------------------------------------
12    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES                    
     CERTAIN SHARES                                                        [_]

--------------------------------------------------------------------------------
13    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)                        

27.6%                                                             
--------------------------------------------------------------------------------
14    TYPE OF REPORTING PERSON                                                  

CO                                                                
--------------------------------------------------------------------------------

SC 13D/A
4th Page of 7
TOC
1st
Previous
Next
↓Bottom
Just 4th
     This Amendment No. 2 (the "Amendment") amends and supplements the Statement
on Schedule 13D, dated November 26, 1999 and filed on December 6, 1999, as      
amended by Amendment No. 1 dated March 10, 2000 and filed on March 15, 2000 (the
"Original Schedule 13D"), relating to the Common Stock, par value $.01 per share
(the "Common Stock"), of Novitron International, Inc., a Delaware corporation   
(the "Issuer").  Mr. Randal J. Kirk ("Mr. Kirk") and Clinical Chemistry         
Holdings, Inc., a Delaware corporation that is controlled by Mr. Kirk ("CCH"    
and, together with Mr. Kirk, the "Reporting Persons"), are filing this Amendment
to update the information in the Original Schedule 13D with respect to the      
beneficial ownership of the Common Stock by the Reporting Persons.              

Item 3.  Source and Amount of Funds or Other Consideration.                     
--------------------------------------------------            

Item 3 of the Original Schedule 13D is hereby amended and supplemented as 
follows:                                                                        

     "On February 14, 2000, Mr. Kirk used approximately $1,530 of personal funds
to purchase 500 shares of Common Stock, and on February 15, 2000, Mr. Kirk sold 
500 shares of Common Stock for approximately $1,470. During the period          
commencing March 16, 2000 and ending May 2, 2000, CCH used approximately $13,460
of working capital to purchase 4,800 shares of Common Stock. During the period  
commencing May 5, 2000 and ending May 16, 2000, Kirkfield, L.L.C., a Virginia   
limited liability company that is controlled by Mr. Kirk ("Kirkfield"), used    
approximately $9,105 of working capital to purchase 3,000 shares of Common      
Stock."                                                                         

Item 5.  Interest in Securities of the Issuer.                                  
-------------------------------------                         

Item 5(a) of the Original Schedule 13D is hereby amended to read in its   
entirety as follows:                                                            

 "The aggregate number and percentage of shares of Common Stock to which
this statement relates is 401,133 shares, representing 27.8% of the 1,441,925   
shares outstanding as reported by the Issuer on February 8, 2000 in the Issuer's
Quarterly Report on Form 10-Q for the quarter ended December 31, 1999 (the most 
recent available filing by the Issuer with the Securities and Exchange          
Commission).  CCH directly beneficially owns 398,133 of the shares to which this
statement relates, and Mr. Kirk could be deemed to have indirect beneficial     
ownership of the shares directly beneficially owned by CCH.  Kirkfield directly 
beneficially owns 3,000 of the shares to which this statement relates, and Mr.  
Kirk could be deemed to have indirect beneficial ownership of the shares        
directly beneficially owned by Kirkfield."                                      

Item 5(b) of the Original Schedule 13D is hereby amended to read in its   
entirety as follows:                                                            

"Each of the Reporting Persons has, together with the other Reporting 
Person, the shared power to vote or direct the vote and the shared power to     
dispose or to direct the disposition of 398,133 shares of Common Stock reported 
by it or him in Item 5(a) hereof.  Mr. Kirk has, together with Kirkfield, the   
shared power to vote or direct the vote and the shared power to                 

Page 4 of 8 Pages 

SC 13D/A
5th Page of 7
TOC
1st
Previous
Next
↓Bottom
Just 5th
dispose or to direct the disposition of 3,000 shares of Common Stock reported by
him in Item 5(a) hereof."                                                       

  Item 5(c) of the Original Schedule 13D is hereby amended and supplemented as
follows:                                                                        

  "The following table lists all transactions in shares of Common Stock by
the Reporting Persons that were effected on February 14, 2000, February 15, 2000
and during the period from March 10, 2000, the date on which Amendment No. 1 to 
this statement was originally filed with the Securities and Exchange Commission,
through June 8, 2000.  All such transactions were effected on The Nasdaq        
SmallCap Market.                                                                

                                                                [Download Table]

                                        Shares Purchased     Average Price  
Reporting Person             Date            (Sold)            Per Share*   
----------------------------------------------------------------------------

                                                                            
Mr. Kirk                    2/14/00              500              $3.00     
Mr. Kirk                    2/15/00             (500)**           $3.00     
CCH                         3/16/00              100              $3.00     
CCH                          4/5/00            2,000              $2.50     
CCH                         4/13/00              600              $2.88     
CCH                         4/14/00            1,200              $3.00     
CCH                          5/2/00              900              $3.00     
Mr. Kirk (Kirkfield)         5/5/00            1,200              $3.00     
Mr. Kirk (Kirkfield)        5/11/00              500              $3.00     
Mr. Kirk (Kirkfield)        5/16/00            1,300              $3.00     

*    Price excludes commission.                                                 

**   Reporting Persons have disgorged profits of $1,669.11 to the Issuer related
    to this sale and the sale by CCH of 10,000 shares of Common Stock on March
13, 2000 in accordance with the requirements of Section 16(b) of the  
Securities Exchange Act of 1934, as amended."                         

Item 7  Material to be Filed as Exhibits.                                       
---------------------------------                               

   The following document is being filed as an exhibit to this Amendment and
is incorporated herein by reference:                                            

Exhibit 7.  Joint Filing Agreement.                                   

Page 5 of 8 Pages 

SC 13D/A
6th Page of 7
TOC
1st
Previous
Next
↓Bottom
Just 6th
SIGNATURE 
--------- 

     After reasonable inquiry and to the best of their knowledge and belief, the
undersigned certify that the information set forth in this statement is true,   
complete and correct.                                                           

Date: June 9, 2000                     /s/ Randal J. Kirk                       
                                  ------------------------------------
            Randal J. Kirk

Date: June 9, 2000                     CLINICAL CHEMISTRY HOLDINGS, INC.        

                         By: /s/ Audrey Ho Ping Ting
                                      --------------------------------
                         Audrey Ho Ping Ting
                                           President and Chief Executive Officer

Page 6 of 8 Pages 

SC 13D/A
Last Page of 7
TOC
1st
Previous
Next
↓Bottom
Just 7th
EXHIBIT INDEX 
------------- 

Exhibit Number           Exhibit                                                
--------------           -------                                                

Exhibit 7.               Joint Filing Agreement.                                

Page 7 of 8 Pages 

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘SC 13D/A’ Filing		Date		First		Last			Other Filings
Filed on:		6/9/00		6					4,  5
		6/8/00		1		5
		5/16/00		4
		5/5/00		4
		5/2/00		4					4,  SC 13G/A
		3/16/00		4
		3/15/00		4					SC 13D/A
		3/13/00		5
		3/10/00		4		5			4
		2/15/00		4		5
		2/14/00		4		5			SC 13G
		2/8/00		4					10-Q
		12/31/99		4					10-Q
		12/6/99		4					3,  SC 13D
		11/26/99		4					3
									List all Filings